A phase-2 trial of low-dose pomalidomide in myelofibrosis

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

In a previous study, we reported on the safety and efficacy of low-dose (0.5 mg) pomalidomide and prednisone and pomalidomide alone (2 mg/day), for the treatment of anemia associated with myelofibrosis (MF). The current study examined the value of low-dose pomalidomide alone. The main eligibility criterion was transfusion-dependency or hemoglobin 10 gm per 100 ml. Anemia response was assessed by International Working Group criteria. Pomalidomide (0.5 mg/day) was given to 58 patients (median age 68 years); 46 (79%) were transfusion-dependent and 42 were JAK2V617F positive. Anemia response was documented only in the presence of JAK2V617F (24 vs 0%; P0.03) but was not further affected by mutant allele burden (P0.39); 9 of the 10 anemia responders became transfusion independent. Anemia response in JAK2V617F-positive patients was predicted by the presence of pomalidomide-induced basophilia in the first month of therapy (38 vs 6%; P0.02) or absence of marked splenomegaly (38 vs 11%; P0.05). A total of 14 (58%) of 24 patients with a platelet count of 100 × 10 9 cells/l experienced a 50% increment in platelet count. There were no spleen responses. Grade 3 or 4 thrombocytopenia/neutropenia occurred in 2%/0% of patients. Low-dose pomalidomide is effective in the treatment of anemia associated with JAK2V617F-positive MF; response is predicted by early drug-induced basophilia.

Original languageEnglish (US)
Pages (from-to)301-304
Number of pages4
JournalLeukemia
Volume25
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Primary Myelofibrosis
Anemia
Platelet Count
Splenomegaly
Prednisone
Neutropenia
pomalidomide
Hemoglobins
Therapeutics
Spleen
Alleles
Safety
Pharmaceutical Preparations

Keywords

  • JAK2
  • lenalidomide
  • myelofibrosis
  • thalidomide
  • treatment

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

A phase-2 trial of low-dose pomalidomide in myelofibrosis. / Begna, Kebede; Mesa, R. A.; Pardanani, Animesh D; Hogan, William; Litzow, Mark R; McClure, R. F.; Tefferi, Ayalew.

In: Leukemia, Vol. 25, No. 2, 02.2011, p. 301-304.

Research output: Contribution to journalArticle

@article{31767d5300a941939f6c9343b825b648,
title = "A phase-2 trial of low-dose pomalidomide in myelofibrosis",
abstract = "In a previous study, we reported on the safety and efficacy of low-dose (0.5 mg) pomalidomide and prednisone and pomalidomide alone (2 mg/day), for the treatment of anemia associated with myelofibrosis (MF). The current study examined the value of low-dose pomalidomide alone. The main eligibility criterion was transfusion-dependency or hemoglobin 10 gm per 100 ml. Anemia response was assessed by International Working Group criteria. Pomalidomide (0.5 mg/day) was given to 58 patients (median age 68 years); 46 (79{\%}) were transfusion-dependent and 42 were JAK2V617F positive. Anemia response was documented only in the presence of JAK2V617F (24 vs 0{\%}; P0.03) but was not further affected by mutant allele burden (P0.39); 9 of the 10 anemia responders became transfusion independent. Anemia response in JAK2V617F-positive patients was predicted by the presence of pomalidomide-induced basophilia in the first month of therapy (38 vs 6{\%}; P0.02) or absence of marked splenomegaly (38 vs 11{\%}; P0.05). A total of 14 (58{\%}) of 24 patients with a platelet count of 100 × 10 9 cells/l experienced a 50{\%} increment in platelet count. There were no spleen responses. Grade 3 or 4 thrombocytopenia/neutropenia occurred in 2{\%}/0{\%} of patients. Low-dose pomalidomide is effective in the treatment of anemia associated with JAK2V617F-positive MF; response is predicted by early drug-induced basophilia.",
keywords = "JAK2, lenalidomide, myelofibrosis, thalidomide, treatment",
author = "Kebede Begna and Mesa, {R. A.} and Pardanani, {Animesh D} and William Hogan and Litzow, {Mark R} and McClure, {R. F.} and Ayalew Tefferi",
year = "2011",
month = "2",
doi = "10.1038/leu.2010.254",
language = "English (US)",
volume = "25",
pages = "301--304",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A phase-2 trial of low-dose pomalidomide in myelofibrosis

AU - Begna, Kebede

AU - Mesa, R. A.

AU - Pardanani, Animesh D

AU - Hogan, William

AU - Litzow, Mark R

AU - McClure, R. F.

AU - Tefferi, Ayalew

PY - 2011/2

Y1 - 2011/2

N2 - In a previous study, we reported on the safety and efficacy of low-dose (0.5 mg) pomalidomide and prednisone and pomalidomide alone (2 mg/day), for the treatment of anemia associated with myelofibrosis (MF). The current study examined the value of low-dose pomalidomide alone. The main eligibility criterion was transfusion-dependency or hemoglobin 10 gm per 100 ml. Anemia response was assessed by International Working Group criteria. Pomalidomide (0.5 mg/day) was given to 58 patients (median age 68 years); 46 (79%) were transfusion-dependent and 42 were JAK2V617F positive. Anemia response was documented only in the presence of JAK2V617F (24 vs 0%; P0.03) but was not further affected by mutant allele burden (P0.39); 9 of the 10 anemia responders became transfusion independent. Anemia response in JAK2V617F-positive patients was predicted by the presence of pomalidomide-induced basophilia in the first month of therapy (38 vs 6%; P0.02) or absence of marked splenomegaly (38 vs 11%; P0.05). A total of 14 (58%) of 24 patients with a platelet count of 100 × 10 9 cells/l experienced a 50% increment in platelet count. There were no spleen responses. Grade 3 or 4 thrombocytopenia/neutropenia occurred in 2%/0% of patients. Low-dose pomalidomide is effective in the treatment of anemia associated with JAK2V617F-positive MF; response is predicted by early drug-induced basophilia.

AB - In a previous study, we reported on the safety and efficacy of low-dose (0.5 mg) pomalidomide and prednisone and pomalidomide alone (2 mg/day), for the treatment of anemia associated with myelofibrosis (MF). The current study examined the value of low-dose pomalidomide alone. The main eligibility criterion was transfusion-dependency or hemoglobin 10 gm per 100 ml. Anemia response was assessed by International Working Group criteria. Pomalidomide (0.5 mg/day) was given to 58 patients (median age 68 years); 46 (79%) were transfusion-dependent and 42 were JAK2V617F positive. Anemia response was documented only in the presence of JAK2V617F (24 vs 0%; P0.03) but was not further affected by mutant allele burden (P0.39); 9 of the 10 anemia responders became transfusion independent. Anemia response in JAK2V617F-positive patients was predicted by the presence of pomalidomide-induced basophilia in the first month of therapy (38 vs 6%; P0.02) or absence of marked splenomegaly (38 vs 11%; P0.05). A total of 14 (58%) of 24 patients with a platelet count of 100 × 10 9 cells/l experienced a 50% increment in platelet count. There were no spleen responses. Grade 3 or 4 thrombocytopenia/neutropenia occurred in 2%/0% of patients. Low-dose pomalidomide is effective in the treatment of anemia associated with JAK2V617F-positive MF; response is predicted by early drug-induced basophilia.

KW - JAK2

KW - lenalidomide

KW - myelofibrosis

KW - thalidomide

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=79751528798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751528798&partnerID=8YFLogxK

U2 - 10.1038/leu.2010.254

DO - 10.1038/leu.2010.254

M3 - Article

C2 - 21052089

AN - SCOPUS:79751528798

VL - 25

SP - 301

EP - 304

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -